108 related articles for article (PubMed ID: 11934810)
1. Neuropeptide Y increases 4-aminopyridine-sensitive transient outward potassium current in rat ventricular myocytes.
Heredia MP; Fernández-Velasco M; Benito G; Delgado C
Br J Pharmacol; 2002 Apr; 135(7):1701-6. PubMed ID: 11934810
[TBL] [Abstract][Full Text] [Related]
2. Activation of neuropeptide Y Y1 receptors inhibits glutamate release through reduction of voltage-dependent Ca2+ entry in the rat cerebral cortex nerve terminals: suppression of this inhibitory effect by the protein kinase C-dependent facilitatory pathway.
Wang SJ
Neuroscience; 2005; 134(3):987-1000. PubMed ID: 16026936
[TBL] [Abstract][Full Text] [Related]
3. Neuropeptide Y rapidly enhances [Ca2+]i transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation.
Heredia Mdel P; Delgado C; Pereira L; Perrier R; Richard S; Vassort G; Bénitah JP; Gómez AM
J Mol Cell Cardiol; 2005 Jan; 38(1):205-12. PubMed ID: 15623437
[TBL] [Abstract][Full Text] [Related]
4. Use of D-myo inositol 1,2,6 trisphosphate to inhibit contractile activity in rat ventricular cardiomyocytes induced by neuropeptide Y and other cardioactive peptides through phospholipase C.
Bell D; Millar BC; McDermott BJ
Br J Pharmacol; 1997 Dec; 122(8):1655-60. PubMed ID: 9422811
[TBL] [Abstract][Full Text] [Related]
5. The plateau outward current in canine ventricle, sensitive to 4-aminopyridine, is a constitutive contributor to ventricular repolarization.
Sridhar A; da Cunha DN; Lacombe VA; Zhou Q; Fox JJ; Hamlin RL; Carnes CA
Br J Pharmacol; 2007 Nov; 152(6):870-9. PubMed ID: 17700726
[TBL] [Abstract][Full Text] [Related]
6. Positive and negative contractile effects of neuropeptide Y on ventricular cardiomyocytes.
Millar BC; Weis T; Piper HM; Weber M; Borchard U; McDermott BJ; Balasubramaniam A
Am J Physiol; 1991 Dec; 261(6 Pt 2):H1727-33. PubMed ID: 1661086
[TBL] [Abstract][Full Text] [Related]
7. Characterization of 4-aminopyridine block of the transient outward K+ current in adult rat ventricular myocytes.
Castle NA; Slawsky MT
J Pharmacol Exp Ther; 1993 Jun; 265(3):1450-9. PubMed ID: 8510021
[TBL] [Abstract][Full Text] [Related]
8. Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway.
Herring N; Lokale MN; Danson EJ; Heaton DA; Paterson DJ
J Mol Cell Cardiol; 2008 Mar; 44(3):477-85. PubMed ID: 17996892
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
Doods HN; Wienen W; Entzeroth M; Rudolf K; Eberlein W; Engel W; Wieland HA
J Pharmacol Exp Ther; 1995 Oct; 275(1):136-42. PubMed ID: 7562541
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptide Y induced attenuation of catecholamine synthesis in the rat mesenteric arterial bed.
Westfall TC; Naes L; Gardner A; Yang CL
J Cardiovasc Pharmacol; 2006 Jun; 47(6):723-8. PubMed ID: 16810071
[TBL] [Abstract][Full Text] [Related]
11. Evidence for Y1-receptor-mediated facilitatory, modulatory cotransmission by NPY in the rat anococcygeus muscle.
Hoyo Y; McGrath JC; Vila E
J Pharmacol Exp Ther; 2000 Jul; 294(1):38-44. PubMed ID: 10871293
[TBL] [Abstract][Full Text] [Related]
12. Effects of insulin on potassium currents of rat ventricular myocytes in streptozotocin diabetes.
Magyar J; Cseresnyés Z; Rusznák Z; Sipos I; Szücs G; Kovács L
Gen Physiol Biophys; 1995 Jun; 14(3):191-201. PubMed ID: 8586253
[TBL] [Abstract][Full Text] [Related]
13. Neuropeptide-Y stimulation of extracellular signal-regulated kinases in human erythroleukemia cells.
Keffel S; Schmidt M; Bischoff A; Michel MC
J Pharmacol Exp Ther; 1999 Dec; 291(3):1172-8. PubMed ID: 10565839
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptide Y contributes to innervation-dependent increase in I(Ca, L) via ventricular Y2 receptors.
Protas L; Robinson RB
Am J Physiol; 1999 Sep; 277(3):H940-6. PubMed ID: 10484414
[TBL] [Abstract][Full Text] [Related]
15. Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: counter regulation through Y1 and Y2/5 receptors.
Dimitrijević M; Stanojević S; Vujić V; Beck-Sickinger A; von Hörsten S
Regul Pept; 2005 Jan; 124(1-3):163-72. PubMed ID: 15544855
[TBL] [Abstract][Full Text] [Related]
16. Vascular neuropeptide Y Y1-receptors in the rat kidney: vasoconstrictor effects and expression of Y1-receptor mRNA.
Modin A; Malmström RE; Meister B
Neuropeptides; 1999 Aug; 33(4):253-9. PubMed ID: 10657500
[TBL] [Abstract][Full Text] [Related]
17. The Galanin N-terminal fragment (1-15) interacts with neuropeptide Y in central cardiovascular control: Involvement of the NPY Y2 receptor subtype.
Díaz-Cabiale Z; Parrado C; Narváez M; Millón C; Puigcerver A; Fuxe K; Narváez JA
Regul Pept; 2010 Aug; 163(1-3):130-6. PubMed ID: 20451563
[TBL] [Abstract][Full Text] [Related]
18. Sympathetic innervation alters activation of pacemaker current (If) in rat ventricle.
Qu J; Cohen IS; Robinson RB
J Physiol; 2000 Aug; 526 Pt 3(Pt 3):561-9. PubMed ID: 10922008
[TBL] [Abstract][Full Text] [Related]
19. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
[TBL] [Abstract][Full Text] [Related]
20. Region specific galanin receptor/neuropeptide Y Y1 receptor interactions in the tel- and diencephalon of the rat. Relevance for food consumption.
Parrado C; Díaz-Cabiale Z; García-Coronel M; Agnati LF; Coveñas R; Fuxe K; Narváez JA
Neuropharmacology; 2007 Feb; 52(2):684-92. PubMed ID: 17087983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
